Graid Technology Secures $30M Series B to Accelerate Growth in Data Storage & Protection Market
New investments will drive expansion of Graid Technology's industry-leading data protection solutions across OEM and Enterprise markets.
SANTA CLARA, CALIFORNIA / ACCESS Newswire / March 4, 2025 / Graid Technology, a leading innovator in GPU-based RAID for NVMe storage performance, today announced the successful closing of its $30 million Series B funding round. The round was led by HH-CTBC Partnership, a joint venture fund between Foxconn and CTBC, alongside Yuanta Ventures. The funding also includes participation from Delta Electronics Capital, Harbinger Venture Capital, and returning investors from Graid Technology's 2022 Series A round.
This investment will drive global expansion, product innovation, and strategic partnerships, strengthening Graid Technology's presence in enterprise and OEM markets while meeting growing demand for AI, machine learning (ML), and high-performance computing (HPC) workloads.
Graid Technology's SupremeRAID™ product line eliminates traditional RAID bottlenecks by offloading RAID operations to the GPU, maximizing NVMe SSD performance and scalability. With thousands of deployments worldwide, SupremeRAID™ is enabling data centers, AI research facilities, media production, and financial institutions to optimize storage infrastructure while ensuring data integrity, redundancy, and resilience.
"This funding marks a significant milestone, not only in expanding our market reach but also in driving new innovations," said Leander Yu, Founder and CEO of Graid Technology. "The backing of HH-CTBC Partnership, Yuanta Ventures, and other strategic investors reflects confidence in our vision. With their support, we are well-positioned to scale our technology and expand into new markets."
About Graid Technology
Graid Technology is transforming enterprise storage with SupremeRAID™, the world's first GPU-based RAID solution. By offloading RAID calculations to the GPU, SupremeRAID™ enables enterprises to maximize NVMe SSD performance, delivering unprecedented speed, efficiency, and scalability for AI, ML, media, and high-performance computing workloads. Headquartered in Silicon Valley, California, with an R&D center in Taipei, Taiwan, Graid Technology partners with leading OEMs and global technology providers to redefine NVMe storage performance.
For more information, visit www.graidtech.com.
Contact Information
SOURCE: Graid Technology Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Tangent Launches Latest Innovation: High-Density Sheet
AURORA, Ill., June 5, 2025 /PRNewswire/ -- Tangent's latest product innovation, high-density sheet, is the ideal alternative material for extraordinary performance applications. This durable, all-weather HDPE sheet affords versatility of design unparalleled by traditional lumber. Affording product flexibility while eliminating unnecessary scrap, Tangent's high-density sheet gives consumers a quality product and builders a competitive advantage. Tangent's high-density sheet is water and moisture resistant, making life easy. No painting or staining is required, and cleaning requires only soap and water. Available in vibrant and trending colors: Black, White, Green, Gray, and Weathered Wood, these colors go beyond the industry standard with additional UV stabilizers to preserve the rich hues. Rigidity and broad span capacity make Tangent's high-density sheet ideal for many applications. This sheet material's durability is proven to withstand extreme force and resist insects, chemicals, and stains, all while handling like wood for build and design needs. Well suited for CNC machining, the product characteristics of Tangent's high-density sheet support clean, precise cuts, smooth edges, and surface routing. It can also be used with standard woodworking tools. Optimal sheet sizes and widths add versatility to Tangent's high-density sheet, helping avoid unnecessary scrap and affording limitless design potential. Strongly supporting waste stream diversion, recycled content is used within production, which is guaranteed by third-party GreenCircle™ Certification. Customization of sheet sizes makes Tangent's high-density sheet the obvious choice as the long-lasting solution for all outdoor projects. Offered in a classic matte, orange peel finish, this high-density sheet product complements the extensive line of profiles available from Tangent's extruded, dimensional lumber product. Max Tremblay, Tangent's Vice President of Engineering, noted, "After years of successfully utilizing our proprietary high-density polyethylene (HDPE) sheets to create millions of diverse furniture items, we are thrilled to announce our decision to extend our expertise to the broader market. With our commitment to quality and innovation, we have established ourselves as one of the largest extruders of HDPE products in North America. We are excited to make this versatile material widely available, empowering industries to collaboratively develop solutions for the challenges they face. Our HDPE sheets are not only durable and sustainable but also offer limitless possibilities for creative applications across various sectors. As we embark on this journey, we are dedicated to becoming the global leader in plastic extrusion products. This initiative marks a significant first step toward achieving that ambitious goal, and we look forward to partnering with businesses and innovators to drive progress in the industry." ABOUT TANGENT TECHNOLOGIESHeadquartered in Aurora, Illinois, Tangent is a leading manufacturer of synthetic lumber used for outdoor living, site amenities, structural applications, and marine decking. In recent years, synthetic lumber has become a leading substitute for traditional fabrication materials in outdoor living products and other applications, given its durability and aesthetics. Tangent uses a combination of post-consumer and post-industrial recycled waste streams as primary raw materials. Media Contact: Sandy Pace Email: Tangent Technologies, LLC Houston, TX 77441 View original content to download multimedia: SOURCE Tangent Materials Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ISG to Evaluate Medical Device Service, Solution Providers
Upcoming ISG Provider Lens™ reports will cover providers helping companies integrate new technologies to make devices more capable, compliant and interoperable STAMFORD, Conn., June 05, 2025--(BUSINESS WIRE)--Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study evaluating digital transformation service and solution providers supporting the medical devices industry, exploring how they help device makers address technology challenges while accelerating innovation and time to market. The study results will be published in two comprehensive ISG Provider Lens™ reports, titled Medical Device Digital Services, covering the U.S. and European markets, respectively, and scheduled to be released in November 2025. The study will examine providers offering medical device companies end-to-end digital engineering and product development services; strategic consulting, quality assurance and regulatory compliance services; and digital solutions for post-market activities. In particular, it will assess provider ability to address technology challenges such as data interoperability and cybersecurity. Enterprise buyers will be able to use information from the reports to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm's buy-side clients. The medical device industry is embracing digital transformation by integrating AI, IoT and cloud technologies. These advancements enhance real-time monitoring and predictive diagnostics, facilitate improved clinical decisions and transform traditional hardware-centric models into dynamic, data-driven ecosystems. "Medical devices are quickly evolving to meet the new requirements of patient-centric healthcare," said Iain Fisher, director, ISG Provider Lens Research. "Device makers need to collaborate with providers on innovation and improve outcomes to remain competitive in the market." ISG has distributed surveys to more than 100 providers of medical device services and solutions. Working in collaboration with ISG's global advisors, the research team will produce three quadrants representing the digital services and solutions most commonly used by medical device companies, based on ISG's experience working with its clients. The three quadrants are: Digital Engineering and Product Development, evaluating providers with expertise in designing and enhancing interconnected, software-driven, compliant medical devices. Providers are assessed on their abilities to apply emerging technologies such as AI, ML, digital twins and edge computing to accelerate innovation, ensure compliance and reduce time to market. Regulatory Compliance, Strategy and Quality Assurance, assessing providers that help medical device manufacturers navigate global regulatory frameworks and align engineering initiatives with go-to-market objectives. Providers implement cybersecurity and data protection strategies, ensuring product and patient safety in connected and software-driven environments. Post-Market Digital Enablement, covering providers that deliver digital solutions for continuous monitoring, device tracking and telehealth integration. Providers focus on developing and integrating remote patient monitoring systems, analytics and post-market surveillance tools. Geographically focused reports from the study will cover digital services and solutions offered to medical device companies in the U.S. and Europe. ISG analysts Rohan Sinha (U.S.) and Sneha Jayanth (Europe) will serve as authors of the reports. A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as digital transformation solution and service providers can contact ISG and ask to be included in the study. All 2025 ISG Provider Lens™ evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG's continuous CX research. Enterprise customers wishing to share their experience about a specific provider or vendor are encouraged to complete this online survey. Participants will receive a copy of this report in return for their feedback. About ISG Provider Lens™ Research The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments. View source version on Contacts Press Contacts: Laura Hupprich, ISG+1 203 517 Julianna Sheridan, Matter Communications for ISG+1 978-518-4520isg@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs. 'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.' This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor. The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
